Shanghai-based biopharmaceutical company EpimAb Biotherapeutics has raised a $74 million Series B round led by SDIC Fund Management and healthcare specialist Sherpa Healthcare Partners.
South China Venture Capital also participated in the funding round, along with investors in the $25 million Series A round such as Oriza Seed Venture Capital, Decheng Capital, and 3E Bioventures Capital....
Sequoia Capital closed its latest set of funds for deployment in India and Southeast Asia with $1.35 billion in commitments.
Ucommune, a Chinese co-working space operator that failed to get traction with an attempted New York IPO last year, has been acquired by a US-listed special purpose acquisition company (SPAC) at a valuation of $764.9 million.
Indies Capital, a Singapore-based GP focused on Indonesia, has reached a first close of $100 million for its third flagship private equity and credit fund.
EQT has submitted a revised offer to acquire New Zealand retirement village player Metlifecare at a lower valuation after facing a legal challenge over its attempt to terminate a previously agreed deal.